PDCD1 and neoplasm: The authors successfully used this platform to model immune checkpoint blockade in vitro by treating both human and mouse tumor organoids with anti-PD1 antibody, which stimulated activation, expansion, and cytotoxicity of tumor-infiltrating lymphocytes [102].